A case of psoriasiform drug eruption induced by sorafenib

Sorafenib is an oral multi-targeted tyrosine kinase inhibitor, which has been used in the treatment of advanced hepatocellular carcinoma (HCC), renal cell cancer.Sorafenib is known to be associated with many dermatological side effects, including hand-foot skin reaction, seborrheic dermatitis-like rash, alopecia, facial erythema.A 67-year-old man with HCC presented with brownish scaly plaque on the trunk and extremities.About 2 weeks before onset of lesions, he received sorafenib treatment for 7 days.Biopsy was performed on trunk, and histologic features showed elongated rete ridge, parakeratosis and also interface change with perivascular eosinophil infiltration.From these findings, we diagnosed the lesion as psoriasiform drug eruption due to sorafenib.Under diagnosis, sorafenib treatment was discontinued and systemic corticosteroid therapy was initiated.During follow-up, the cutaneous lesions were gradually improved.Herein, we report a case of psoriasiform drug eruption induced by sorafenib, emphasizing the need for clinicians to recognize this rare adverse effect.